Company intelligence / Profile preview

Arresto BioSciences

Palo Alto, California, United Statesgilead.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Arresto BioSciences was a biotechnology company focused on developing medicines for cancer and fibrotic diseases by targeting extracellular matrix proteins such as LOXL2. Its lead candidate, AB0023, targeted LOXL2 for the treatment of neoplasms. The company built a pipeline leveraging novel mechanisms to impact bone, connective tissue disorders, fibrosis, and oncology. Arresto was acquired by Gilead Sciences in late 2010; its programs have since been integrated into Gilead’s R&D efforts.[1][2]

Therapeutic areas: OncologyRheumatologyOther
Modalities: Small molecules and biologics targeting extracellular matrix proteins and enzymes[1][3]
Industry: Biotech

Drug pipeline

1 asset

AB0024

Phase 1

Indications: Idiopathic pulmonary fibrosis, Advanced solid tumors

Beyond the preview

Go deeper on Arresto BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arresto BioSciences.

Explore the full profile